New York City, NY -- (SBWIRE) -- 10/18/2013 -- StockMarketIntel.com issues a special report on the following stocks: OncoSec Medical Inc (OTCMKTS:ONCS), Alkermes Plc (NASDAQ:ALKS), ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), Incyte Corporation (NASDAQ:INCY)
OncoSec Medical Inc (OTCMKTS:ONCS) gained 3.01%, trading on 1.95 million shares, to end the trade at $0.288. If we look at its trading history of the past 52 weeks, the share price suffered a low of $0.18 and was moved to the maximum level of $0.49. The stock changed hands in a range of $0.28 to $0.29, bringing its market capitalization to about $25.45 million. OncoSec Medical Incorporated is an emerging drug-medical device company. The Company focused on designing, developing and commercializing medical approaches for the treatment of solid cancers. In March 2011, the Company acquired from Inovio Pharmaceuticals, Inc. (Inovio) certain assets related to the use of drug-medical device combination products for the treatment of different cancers.
What was the Moving Force behind ONCS on Bullish Run? Read This Research Report
Alkermes Plc (NASDAQ:ALKS) added 8.46%, to complete the trading session at $35.38, with a total volume of 1.80 million shares. The stock, on average, trades on a volume of 778,922 shares. In the past 52 weeks, the share price has not declined below $18.00 and above $35.72. It floated in a range of $32.66 to $35.39 during the last trading session, with a beta value of 0.98. Its market capitalization now moved to about $4.80 billion. Alkermes plc., formerly Alkermes, Inc., is an integrated biotechnology company. The Company is engaged in the business of developing, manufacturing and commercializing medicines for the treatment of prevalent, chronic diseases. The Company develops, manufactures and commercializes VIVITROL for alcohol dependence and manufacture RISPERDAL CONSTA for schizophrenia and bipolar I disorder.
For How Long ALKS will fight for Profitability? Read This Trend Analysis report
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) recorded a fall of -2.40% and was in a range of $32.92-$34.41 before closing at $33.35. The share price hit its 52-week low of $7.55 and $39.83 was the best price. The stock completed the day with a total volume of 1.65 million shares, versus an average volume of 1.77 million shares.
Has ISIS Found The Bottom and Ready To Move Up? Find Out Here
Incyte Corporation (NASDAQ:INCY) declined -1.94% yesterday, bringing its market capitalization around $5.87 billion. The total number of shares that changed hands during the session was 1.57 million shares, as compared to average trading volume of 1.65 million shares. The share price, after opening at $38.98, made a high of $39.07 and hovered above $37.80 to end the day at $38.35. Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. Its advanced compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF.
Has INCY Found The Bottom And Ready To Gain Momentum? Find Out Here
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)